PERSPECTA

News from every angle

← Back to headlines

Goldman Sachs Sees Limited Upside for Dr. Reddy’s Laboratories

Goldman Sachs has issued an outlook indicating limited upside potential for Dr. Reddy’s Laboratories Limited (RDY), citing concerns related to generic drugs.

11 May, 20:06 — 11 May, 20:06
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual14d ago

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

Read full article →

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

DENR Backs Tree-Cutting for Palawan Nickel Project

just now

Economy robust, external factors putting pressure on 3 Fs: Nirmala Sitharaman

21m ago

Indian Government to Standardise Edible Oil Packaging to End Price Confusion

40m ago